Get started
Author

Sathej Gopalakrishnan

Observed names: Gopalakrishnan, Sathej, S. Gopalakrishnan, Sathej M. Gopalakrishnan
Observed institutions: Merck KGaA, Darmstadt (Germany), University of Potsdam, AbbVie (United States), AbbVie (Germany), Merck Healthcare KGaA, Darmstadt (Germany), Freie Universität Berlin
ORCID: 0000-0003-0923-034X
Observed ORCID: 0000-0003-0923-034X
OpenAlex ID: A5017450000
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
2020 · Andrew H. Wei, Pau Montesinos, et al. · Blood · 763
PDF
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials
2024 · Xavier Montalban, Patrick Vermersch, et al. · The Lancet Neurology · 88
Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy
2022 · Deanna Brackman, Doerthe Eckert, et al. · Hematological Oncology · 46
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure‐response analysis
2019 · Suresh Agarwal, Sathej Gopalakrishnan, et al. · Hematological Oncology · 43
Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug–drug interaction studies
2022 · Jayaprakasam Bolleddula, Sathej Gopalakrishnan, et al. · Clinical and Translational Science · 35
PDF
Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials
2021 · Elena Muensterman, Benjamin Engelhardt, et al. · Clinical and Translational Science · 35
Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma
2017 · Apurvasena Parikh, Sathej Gopalakrishnan, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 26
Asia‐Inclusive Global Development of Enpatoran: Results of an Ethno‐Bridging Study, Intrinsic/Extrinsic Factor Assessments and Disease Trajectory Modeling to Inform Design of a Phase II Multiregional Clinical Trial
2024 · Lena Klopp‐Schulze, Sathej Gopalakrishnan, et al. · Clinical Pharmacology & Therapeutics · 24
Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection
2016 · Sathej M. Gopalakrishnan, Akshanth R. Polepally, et al. · Clinical Pharmacokinetics · 17
Exposure‐Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis—Analyses of Phase 2b Study to Support Selection of Phase 3 Doses
2020 · Mohamed‐Eslam F. Mohamed, Sathej Gopalakrishnan, et al. · The Journal of Clinical Pharmacology · 12
PDF
Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia
2020 · Sathej Gopalakrishnan, William Wierda, et al. · Clinical Pharmacology & Therapeutics · 12
Model‐Informed Dosing of Venetoclax in Healthy Subjects: An Exposure−Response Analysis
2019 · Nimita Dave, Sathej Gopalakrishnan, et al. · Clinical and Translational Science · 11
PDF
Dosing of Venetoclax in Pediatric Patients with Relapsed Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response Relationships
2024 · Mohamed Badawi, Sathej Gopalakrishnan, et al. · Clinical Therapeutics · 8
PDF
Venetoclax in biomarker‐selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety
2023 · Mohamed Badawi, Sheryl Coppola, et al. · Hematological Oncology · 7
Proposed Scheme for Dosing Venetoclax in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response Relationships
2020 · Mohamed A Badawi, Sathej Gopalakrishnan, et al. · Blood · 4
Exposure–Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study
2016 · Sathej Gopalakrishnan, Amit Khatri, et al. · Advances in Therapy · 3
Estimating HIV-1 Fitness Characteristics from Cross-Sectional Genotype Data
2014 · Sathej Gopalakrishnan, Hesam Montazeri, et al. · PLoS Computational Biology · 3
PDF
Sustained Minimal Residual Disease Negativity Predicted in Chronic Lymphocytic Leukemia Patients Treated with Venetoclax Combination Therapy for 2 Years: an Integrated Mechanistic Analysis of Multiple Phase I and II Studies
2017 · Sathej Gopalakrishnan, Brenda Chyla, et al. · Blood · 2
Oral Cladribine Capsules for Generalized Myasthenia Gravis: Design of the Actively Recruiting Phase 3 MyClad Study (P1-11.013)
2025 · Konrad Rejdak, James F. Howard, et al. · Neurology · 1
Evobrutinib pathway to its major metabolite M463-2 and insights from a biotransformation and DDI perspective
2023 · Holger Scheible, Hanno Schieferstein, et al. · Xenobiotica · 1
PDF
Pos0755 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Orally Administered Dose of Enpatoran in a Phase I Study of Healthy Japanese and Caucasian Participants
2022 · S. Gopalakrishnan, A. Krebs-Brown, et al. · Annals of the Rheumatic Diseases · 1
PDF
POS1054 UPADACITINIB PHARMACOKINETICS AND EXPOSURE-RESPONSE RELATIONSHIPS FOR EFFICACY AND SAFETY IN PSORIATIC ARTHRITIS – ANALYSES OF THE PHASE 3 SELECT-PsA STUDIES
2021 · E. Muensterman, B. Engelhardt, et al. · Annals of the Rheumatic Diseases · 1
PDF
Venetoclax Exposure-Efficacy and Exposure-Safety Relationships in Subjects with Treatment-Naïve Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
2020 · Doerthe Eckert, Deanna Brackman, et al. · Blood · 1
MDS-141: The Prognostic Impact of Cytogenetic Scores in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Venetoclax and Azacitidine in a Phase 1 Study
2020 · Jacqueline S Garcia, Andrew H Wei, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Hepatitis C Virus-Infected Cirrhotic and Non-cirrhotic Patients: Analyses Across Nine Phase III Studies
2018 · Sathej Gopalakrishnan, Sven Mensing, et al. · Clinical Pharmacokinetics · 1
Works count: 35
Citation count: 1,146
H-index: 11
I10-index: 12
Year
Topic
Type